Article
Findings from a large Asian chronic hepatitis C real-life study.
Journal of viral hepatitis - 1 Dec 2018
Lim Seng Gee, Phyo Wah Wah, Shah Samir R, Win Khin Maung, Hamid Saeed, Piratvisuth Teerha, Tan Soek Siam, Dan Yock Young, Lee Yin Mei, Ahmed Taufique, Yang Wei Lyn, Chen Kok Pun, Kamat Mrunal, Wadhawan Manav, Madan Kaushal, Mehta Rajiv, Shukla Akash, Dhore Prashant, Eapen Chundamannil E, Abraham Priya, Tyagi Satyendra, Koshy Abraham, Bwa Aung Hlaing, Jafri Wasim, Abid Shahab, Arisar Fakhar Ali Qazi, Tanwandee Tewesak, Yin Thing Phee, Tee Hoi Poh, Hj Md Said Rosaida Binti, Goh Khean Lee, Ho Shiaw Hooi, Mohamed Rosmawati, Abu Bakar Norasiah
Abstract excerpt
There is a paucity of information on chronic hepatitis C (CHC) patients treated with direct antiviral agents (DAAs) in Asia. We invited Asia-Pacific physicians to collate databases of patients enrolled for CHC treatment, recording baseline clinical, virologic and biochemical characteristics, sustained virologic response at week 12 (SVR12) and virologic failure. SVR12 outcome was based on intention to treat (ITT)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
